|Bid||11.95 x 0|
|Ask||12.04 x 0|
|Day's Range||11.48 - 11.61|
|52 Week Range||11.48 - 26.95|
|Beta (3Y Monthly)||0.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Revance Therapeutics Inc is a clinical-stage biopharmaceutical company. Revance Therapeutics Inc had annual average EBITDA growth of 21.60% over the past five years. Warning! GuruFocus has detected 5 Warning Signs with RVNC.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs Jan. 15) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) Avenue Therapeutics ...
A potential rival for Allergan Plc's blockbuster Botox has passed a late-stage study, putting drug developer Revance Therapeutics Inc on course to file for U.S. marketing approval next year. More than 95 percent of patients administered with Revance's long-acting neuromodulator injection RT002 were found to have none or mild frown lines after four weeks, according to data from the third late-stage study. The treatment, which requires two or less doses a year, was effective in maintaining reduced wrinkle severity in patients for a median duration of 24 weeks.
If you’re interested in Revance Therapeutics Inc (NASDAQ:RVNC), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
Revance Therapeutics Inc (NASDAQ: RVNC ), a biotech company developing a botulinum toxin product, could face a competitive backlash, according to JMP Securities. The Analyst Analyst Donald Ellis downgraded ...
Individual investors like stocks with a high growth potential. These companies have a strong outlook that can bring a significant upside to your portfolio, regardless of market cyclicality. The listRead More...
Most investors find it challenging to find companies with prospective double-digit growth rates that are also financially robust. These hidden gems also add meaningful upside to a portfolio, should theRead More...
Botox faces a delay in getting to market, Allergan is anything but frozen. "Of course, it's always interesting when a company takes more time to get to market," Allergan chief commercial officer William Meury said at the Bank of America healthcare conference in Las Vegas on Thursday, May 17. Meury's appearance at the conference came a day after competitor Evolus Inc.
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the expansion of its executive leadership team with the appointment of Caryn McDowell as Senior Vice President, General Counsel, and Corporate Secretary, effective May 1, 2018. Ms. McDowell will report to President and Chief Executive Officer Dan Browne, and will serve as Revance’s General Counsel, leading all legal, governance, and compliance initiatives. “Caryn brings extensive legal experience in the biopharma and healthcare sectors, advising companies developing and commercializing novel drug products,” said Mr. Browne.
Patients are already clamoring for “the longer acting Botox,” a not-yet approved treatment from Revance Therapeutics, CEO Dan Browne told Bloomberg News in an interview Friday. The launch won’t happen for another two years or so, and while many patients want more time looking younger, doctors are looking for a longer acting product for therapeutic goals. "People underestimate the power of this data,” Browne said, he’s expecting it to be a “major de-risking event” for Revance when results from the study, known as “Sakura” read out later this year.